CSX vs ZYME · P/E 19, rev $14.09B vs rev $76.3M
CSX Corporation (CSX) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
CSX Corporation (CSX) is a railroads company listed on US.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported CSX revenue for 2025-12-31 was $14.09B. Net income was $2.89B. Revenue was down 3.1% from 2024-12-31 to 2025-12-31. CSX currently screens at market cap $61.18B and trailing P/E 19.4.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
CSX currently screens at market cap $61.18B and trailing P/E 19.4. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the CSX and ZYME stock pages for the full models.
Not investment advice.